OrbiMed’s Amarin Corp AMRN Stock Holding History

OrbiMed’s Portfolio AMRN Stock Details AMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-17,500	Closed	-$7.27M	–	129
2019 Q1	$7.27M	Buy	+17,500	New	+$6.31M	0.11%	95

Other funds holding AMRN

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

OrbiMed's AMRN Position: Q1 2020 in Review

OrbiMed sold out of Amarin Corp (AMRN) in Q1 2020, closing a stake of 12,480 shares — an estimated $5.35M sold.

OrbiMed first reported a position in AMRN in Q2 2013 and held it in 22 quarters. The position peaked at $13.9M in Q2 2019. 306 funds tracked by Wall St. Rank hold AMRN as of Q1 2020.

OrbiMed reported no remaining Amarin Corp position as of Q1 2020 after selling out during the quarter.
OrbiMed sold 12,480 Amarin Corp shares in Q1 2020, an estimated $5.35M.
OrbiMed first reported a position in Amarin Corp in Q2 2013 and held it in 22 quarters.
OrbiMed's Amarin Corp position peaked at $13.9M in Q2 2019.
306 funds tracked by Wall St. Rank held Amarin Corp as of Q1 2020.

Based on OrbiMed's 13F filing for Q1 2020, filed 15 May 2020.